Brussels (ots/PRNewswire) - A unique joint declaration by AIDS activists, doctors, researchers, pharmaceutical companies and members of regulatory agencies has been issued demanding the urgent development of better treatment options for people co-infected with the HIV and hepatitis C (HCV) viruses. The ...
Berlin, Germany (ots/PRNewswire) - Dr. Bruno Demichelis, world-renowned sports psychologist, addressed the BFE's Annual meeting in Berlin on AC Milan's use of the Mind Room and Sport Psychology/Sports Medicine. The MindRoom, which includes Thought Technology's ProComp Infiniti/BioGraph Infiniti, is considered ...
Vienna, Austria (ots/PRNewswire) - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced new data that showed that, in moderate to severe plaque psoriasis patients, ENBREL(R) (etanercept) reduced the severity of nail psoriasis by more than 28 percent at 12 weeks and reduced the signs and ...
Paris (ots/PRNewswire) - - Lovenox(R) is the Low-Molecular Weight Heparin, Approved in the United States for the Broadest Range of Indications Sanofi-aventis announced today that the Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for the anticoagulant Lovenox(R) ...
Lugano (ots) - With reference to the Irish Medicine Board (IMB) decision, mainly based on 6 cases of hepatic damage, to suspend the marketing and sale of nimesulide and following the request to the European Committee for Medicinal Products for Human Use (CHMP) to revise the benefit/risk profile of the drug, Helsinn Healthcare deems opportune to specify that nimesulide is a drug with a positive safety profile as ...
Irvine, California (ots/PRNewswire) - IsoTis, Inc (NASDAQ: ISOT), an orthobiologics company, today reported results for the first quarter ended March 31, 2007. Revenue Analysis Revenue was US$10.0 million for the first quarter of 2007, representing a 2% increase over revenue of US$9.8 million for the first quarter of 2006. IsoTis' chief distribution channels are its U.S. network of independent distributor ...
Tokyo (ots/PRNewswire) - Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced that the company has signed on May 14, 2007 (the U.S. Eastern Time) the exclusive agreement with Solstice Neurosciences, Inc. (Headquarters: Pennsylvania, U.S., President & CEO: Shawn Patrick O'Brien) for NeuroBloc(R) , an injectable form of botulinum toxin ...
Collegeville, Pennsylvania and Tarrytown, New York (ots/PRNewswire) - - Application for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced today that Wyeth has ...
Pittsburgh (ots/PRNewswire) - - Combination Creates a World Class Global Generics Leader - - Significant Scale and Breadth Will Drive Major Operating Efficiencies - - Highly Complementary Transaction Further Strengthens Mylan's Product Portfolio - - Accelerates Mylan's Revenue and Earnings Growth - - Anticipated to be Cash EPS(1) Neutral in 2nd Full Year - Mylan Laboratories Inc. (NYSE: MYL) ...
Boxmeer, The Netherlands (ots/PRNewswire) - Intervet, a leading animal health company, received approval for its bird flu (avian influenza) vaccine Nobilis(R) Influenza H7N1. As a result, Europe now has a licensed vaccine to protect birds against the H7 field strain. Last year the European Commission approved Nobilis(R) Influenza H5N2. With the registration Intervet confirms its leading position in AI vaccines ...
Ingelheim, Germany (ots/PRNewswire) - - Trial to Compare Efficacy and Safety of Viramune(R) (Nevirapine) Versus Atazanavir/Ritonavir in Treatment-Naive Patients Boehringer Ingelheim GmbH announced today that it has initiated and begun enrollment of patients in the ArTEN trial, which will compare the efficacy and safety of Viramune(R) (nevirapine), ...
Basel, Switzerland (ots/PRNewswire) - Results of the landmark VICTOR study presented today at the American Transplant Congress, San Francisco, USA, have shown that Valcyte (oral valganciclovir) is as effective and as well tolerated as intravenous ganciclovir, the current gold-standard for the treatment of ...
Irvine, California (ots/PRNewswire) - IsoTis, Inc (NASDAQ: ISOT), a leading orthobiologics company, will release its first quarter 2007 results on May 15 at approximately 4:30 p.m. EST . To discuss these results, the Company will conduct a conference call at 5 p.m. EST / 2:00 p.m. PST/ 11:00 p.m. CET. US Dial In: 1-617-614-6206; UK Dial In +44-20-7365-8426; Continental Europe Dial In: +41-1-800-9569; password: ...
Lugano (ots) - HELSINN HEALTHCARE SA, a privately owned Swiss pharmaceutical group, today announced that a supplemental New Drug Application (sNDA) for Aloxi® (palonosetron hydrochloride) Injection for the prevention of post-operative nausea and vomiting (PONV) has been submitted to the U.S. Food and Drug ...
Edmonton, Alberta (ots/PRNewswire) - Isotechnika Inc. today announced the audited three month results, reviewed by the Data Monitoring Committee, of the first third of the patients treated in its Phase 2b de novo kidney transplant trial for the Company's lead immunosuppressive drug, ISA247. This interim analysis is based upon the assessment of the first 116 ...
Edmonton, Alberta (ots/PRNewswire) - Isotechnika Inc. will announce interim three month data from its Phase 2b kidney transplant trial for the Company's lead immunosuppressive drug, ISA247 on Monday, May 7th at 6:00 a.m. ET/4:00 a.m. MT. The management team will provide a review of the Phase 2b kidney transplant trial via a live conference call on Monday, May 7th ...
Copenhagen, Denmark (ots/PRNewswire) - - New Data Show Clear Benefit of Protelos(R) in Wide Range of Osteoporosis Patients Irrespective of Disease Severity New, long term data presented at the 34th European Symposium on Calcified Tissues (ECTS) this week underscore the unmatchable, long-term efficacy and ...
Calgary , Canada (ots/PRNewswire) - In the news release, "SemBioSys Announces First Quarter Results" issued on 3 May 2007 11:00 GMT, by SemBioSys Genetics Inc. TSX:SBS over PR Newswire, we are advised by a representative of the company that errors occurred in the headings of the financial tables. The comparative years were transposed by CNW in error. Complete corrected copy follows: - SemBioSys Announces First ...
Edmonton, Canada (ots/PRNewswire) - - Trades on Toronto Stock Exchange - (TSX:ISA) Isotechnika today announced that the Company has been selected to give an oral presentation during the American Transplant Congress in San Francisco, California. An overview of the latest Phase 2b kidney transplant trial (PROMISE) results will be presented during an oral ...
Irvine, California (ots/PRNewswire) - IsoTis, Inc. (NASDAQ: ISOT), the orthobiologics company, today announced that the United States Patent and Trademark Office has awarded US Patent No. 7,205,337, which relates to the company's Reverse Phase Medium (RPM) carrier technology. The patent covers the use of IsoTis' current RPM technology in combination with various demineralized bone matrix (DBM) formulations, such as ...
Calgary , Canada (ots/PRNewswire) - - Canadian Biotechnology Company Achieves Insulin Milestones and Strengthens Balance Sheet SemBioSys Genetics Inc. (TSX:SBS), a biotechnology company developing insulin and other metabolic and cardiovascular protein-based pharmaceuticals and a series of non-pharmaceutical products, today announced its operational and financial results for the 2007 first quarter which ...
Toronto (ots/PRNewswire) - "The Beijing 2008 Summer Olympics promises to be an historic event for the world of sports and for people worldwide," says Secretary-General Ban Ki-moon's Special Adviser on Sport for Development and Peace. Adolf Ogi has scheduled a meeting with Liu Qi, President of the Beijing ...
Evry, France (ots/PRNewswire) - The 2007 edition of the BIO (Biotechnology Industry Organization) trade show will be held in Boston (may 6-9). Genopole will attend this major event as part of a delegation coordinated by the Paris Il-de-France Regional Development Agency (ARD). Three innovative companies supported by Genopole(R) - Genewave, MATBiopharma and Vaxon ...
Astellas Pharma Europe Limited
London (ots/PRNewswire) - Astellas announced today that the European Commission has approved the immunosuppressant Advagraf(R) (generic name: tacrolimus, prolonged release) for prophylaxis of transplant rejection in adult kidney or liver allograft recipients and for the treatment of allograft rejection ...
Basel, Switzerland (ots/PRNewswire) - - Newly published results show significant improvement in survival when innovative, oral cancer drug Tarceva is added to chemotherapy New results published by the Journal of Clinical Oncology show that adding Tarceva (erlotinib) to gemcitabine chemotherapy significantly improves survival by 22 percent in patients with advanced pancreatic cancer.(1) This survival ...
Irvine, California (ots/PRNewswire) - IsoTis, Inc. (NASDAQ: ISOT), the orthobiologics company, today announced it has completed the transfer of the rights associated with its PolyActive technology to OctoPlus (Euronext: OCTO), a drug delivery and development company, in exchange for an up-front payment of approximately $1.7 million and future royalty payments on sales of pharmaceutical products based on the ...
Basel, Switzerland (ots/PRNewswire) - - Findings Illustrate Role of Innovative New Treatment in Population Most Affected by Chronic Kidney Disease A new Roche Phase III analysis shows once-monthly MIRCERA, a continuous erythropoietin receptor activator, effectively treats renal anaemia in one of the ...
Toronto, Canada (ots/PRNewswire) - - Vasogen to Host Conference Call Today at 9:00 a.m. (ET) Vasogen Inc. (NASDAQ:VSGND; TSX:VAS) today announced a collaboration with Grupo Ferrer Internacional, S.A. ("Ferrer"), a leading European pharmaceutical and medical devices company, to commercialize Vasogen's Celacade(TM) technology for the treatment of chronic ...
Los Angeles (ots/PRNewswire) - - Awards Presented for Substantial Contributions to Cancer Research Innovative and collaborative cancer research can be the catalyst to improving patient outcomes. Celebrating the 100th anniversary of the American Association for Cancer Research (AACR) at the 2007 AACR Annual Meeting in Los Angeles, Eli Lilly and Company in ...
Irvine, California (ots/PRNewswire) - In the news release, "IsoTis Appoints James P. Abraham as Senior Vice President Sales" issued on 16 Apr 2007 12:00 GMT, by Isotis Inc nasdaq:ISOT over PR Newswire, we are advised by a representative of the company that the release is the same for several wire tasks, so the destinations will be added to this task transmitted by PR Newswire. Complete, corrected release follows: ...